NEW ORLEANS—Relative to ibrutinib, the second-generation Bruton tyrosine kinase inhibitor zanubrutinib was more effective and safer for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the multinational ALPINE study.
The study was a head-to-head comparison of zanubrutinib (Brukinsa, Beigene) and ibrutinib (Imbruvica, Janssen/Pharmacyclics) in patients with R/R CLL/SLL who had received at least one prior line of